20 años de evidencia: Cómo se posicionan el primer anticuerpo monoclonal y su biosimilar en el saturado panorama de la esclerosis múltiple

20 Years of Evidence: How the First Monoclonal Antibody and Its Biosimilar Fit Into a Crowded Multiple Sclerosis Landscape Authors: Gavin Giovannoni, MD; Thomas Berger, MD; Diego Centonze, MD, PhD https://www.medscape.org/viewarticle/twenty-years-monoclonal-antibody-biosimilar-ms-2026a1000wl8?page=2&subtitle-lang-code=es